Your Contact. News Release Xxxxxxx Xxxxxx Phone +0-000-000-0000
Your Contact. You will designate an individual who will have the responsibility to, and the authority of You, to make decisions concerning all matters relating to this Agreement (“Primary Contact”). You may change the individual designated as Primary Contact at any time by updating the information in the administration console for the Services.
Your Contact. Xx. Xxxxxx Xxxxxxxx
Your Contact. Rank/Name
Your Contact. You must designate a contact person (“Your Contact”) with whom Vital-Sim will communicate in relation to Support. You must notify Vital-Sim of the contact details, and any changes to those contact details, for Your Contract including telephone and facsimile numbers and email addresses. You may change Your Contact at any time by giving Vital-Sim reasonable notice of such change. Your Contact must be trained in the use of the Software, familiar with the Documentation and devote any necessary time and effort to assist Vital-Sim in resolving Problems in accordance with this Agreement. You will be solely responsible for any costs or expenses You incur in performing Your obligations under this Agreement, including the cost of any telecommunications or internet access charges. Your Contact can contact Vital-Sim by: telephoning 000-000-0000; sending an email to support@vital-sim; or using the support that may be available on Vital-Sim’s website. Support does not include: installation, training, configuration, customization or other services not expressly described in Section 0; help with any Problem caused by: Your use of the Licensed Materials other than in accordance with this Agreement; modifications or alterations to the Licensed Materials not made by Vital-Sim; use of the Licensed Materials in connection or combination with equipment, devices or software that are not specified in writing by Vital-Sim as being compatible with the Software; Your failure to implement any Patches or Updates that are made available to You or; Your failure to implement any New Release of the Software, if Vital-Sim has given You at least 180 days’ notice that it will no longer be supporting previous releases of the Software; or any Support provided by Vital-Sim, at Your request, which is outside Business Hours or at Your facilities, (together the “Excluded Services”). Vital-Sim may, but is under no obligation to, perform such Excluded Services for You upon receipt of a request to do so.
Your Contact. You are required to designate one or more payroll contacts that will serve as Your authorized representative in Your dealings with Us, and We shall have the right to rely on the representation, directives, and information provided by this contact(s) in performing payroll related services. You acknowledge that You are responsible for the accuracy of Your information provided by the payroll contact(s) and/or You.
Your Contact. Xx. Xxxxxx Xxxxxxxx News Release Phone +00 0000 00-0000 June 24, 2014 Merck Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates · Collaboration and license agreement allows Merck Serono to expand its oncology drug portfolio · Mersana Therapeutics’ Fleximer technology to be leveraged to create multiple antibody-drug conjugates Darmstadt, Germany, June 24, 2014 — Merck Serono, the biopharmaceutical division of Merck, and Mersana Therapeutics, Inc., Cambridge, Mass., U.S., announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells which could lead to higher drug levels at the tumor site. Mersana and Merck Serono will leverage Mersana’s Fleximer® technology to generate ADCs for multiple undisclosed targets. Both parties have agreed to test a variety of ADCs by utilizing Mersana’s platform technologies, and several cytotoxic agents as conjugates. This agreement further underlines Merck Serono’s approach to employ a collaborative research and development model, creating strategic partnerships to drive innovation, being consciously agnostic of the source of potential novel assets, and technologies. “This new collaboration provides an exciting opportunity to expand our oncology drug discovery and development portfolio into the evolving ADC space,” said Xx. Xxxxxx Xxxxxxx, head of the Translational Innovation Platform Oncology at Merck Serono. “At Merck Serono, we have a long standing commitment to improving oncology care, and we aim to deliver the best benefit possible to patients. Partnering with Mersana allows us to incorporate cutting edge research and technical excellence to enrich our pipeline.” “We look forward to working with Merck Serono to apply our proprietary platform technologies to rapidly develop and demonstrate preclinical proof-of-concept of several customized, novel Fleximer-ADC candidates,” said Xxxxxxx X. Xxxxxxxx, Ph.D., Mersana’s Chief Scientific Officer. Under the agreement, Merck Serono will provide monoclonal antibodies to Mersana who will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities. [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Merck Serono wi...
Your Contact. Rank/Name Phone Fax E-Mail
